In this deep-dive episode, we unpack ProlivRx for Depression: At-Home Neuromodulation PMHNPs Should Know. Audio Overview Listen to an in-depth podcast of this post Two hosts break down the full article — no reading required. Your browser does not support audio playback. 56% of patients hit remission or mild status by week 16 — without adding another pill. That’s the headline finding from the MOOD trial, the clinical study behind ProlivRx, the first FDA-approved prescription at-home brain neuromodulation device for major depressive disorder. Approved through the rigorous Class III Premarket Approval pathway in late 2025 and now rolling out across behavioral health programs, ProlivRx gives PMHNPs a fundamentally different tool for the patients who haven’t responded adequately to antidepressants alone. For early-career PMHNPs managing complex depressi ...